Colon Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Colorectal Cancer (1365)

Rectal Cancer (90)

Colorectal Adenocarcinoma (9)

Colorectal Cancer (1365)

Rectal Cancer (90)

Colorectal Adenocarcinoma (9)

›

No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
NTRK3 fusion	Colon Cancer	NTRK3 fusion	Colon Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Colon Cancer	NTRK1 fusion	Colon Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Colon Cancer	NTRK2 fusion	Colon Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive : A2	5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive : A2
RET fusion	Colon Cancer	RET fusion	Colon Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	Resistant: A2 - Guideline Resistant : A2	Resistant: A2 - Guideline Resistant : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
KRAS wild-type	Colon Cancer	KRAS wild-type	Colon Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	ziv-aflibercept IV Sensitive: A2 - Guideline ziv-aflibercept IV Sensitive : A2	ziv-aflibercept IV Sensitive: A2 - Guideline ziv-aflibercept IV Sensitive : A2
BRAF wild-type	Colon Cancer	BRAF wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
KRAS wild-type	Colon Cancer	KRAS wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2

Colon Cancer

Associations(172)

Associations
(172)